Table 5.
Results of the logit model demonstrating country differences by adolescent and child groups in order of preference (only significant results are shown)
| Adolescents | Children | |||
|---|---|---|---|---|
| OR (SE) | 95 % CI | OR (SE) | 95 % CI | |
| Countrya (reference: UKb) | ||||
| Netherlands | 2.92 (1.19) | 1.31, 6.48 | – | – |
| Germany | 9.87 (5.01) | 3.65, 26.7 | – | – |
| Spain | – | – | 0.55 (0.17) | 0.31, 1.00 |
| Degree of symptom control (reference: UK) | ||||
| Much improved | 3.68 (0.47) | 2.88, 4.72 | 3.75 (0.49) | 2.91, 4.84 |
| Very much improved | 8.45 (1.18) | 6.44, 11.11 | 5.87 (0.81) | 4.48, 7.68 |
| Spain × much improved symptoms | 0.64 (0.12) | 0.44, 0.92 | ||
| Spain × very much improved symptoms | 0.39 (0.08) | 0.26, 0.58 | 1.55 (0.29) | 1.07, 2.23 |
| Italy × much improved symptoms | 0.45 (0.09) | 0.31, 0.66 | 0.56 (0.09) | 0.41, 0.77 |
| Italy × very much improved symptoms | 0.27 (0.06) | 0.18, 0.4 | 0.50 (0.09) | 0.36, 0.71 |
| France × much improved symptoms | 0.54 (0.11) | 0.37, 0.8 | – | – |
| France × very much improved symptoms | 0.38 (0.08) | 0.25, 0.58 | – | – |
| Duration of symptom control (reference: UK) | ||||
| 10 h | 1.49 (0.19) | 1.16, 1.91 | 1.52 (0.20) | 1.17, 1.95 |
| 12 h | 1.88 (0.25) | 1.45, 2.44 | 1.81 (0.24) | 1.39, 2.34 |
| Italy × 12 h symptom control | – | – | 0.66 (0.11) | 0.48, 0.92 |
| Potential of treatment abuse (reference: UK) | ||||
| UK 1 % increase in potential of treatment abuse | 0.97 (0.01) | 0.96, 0.99 | N/A | N/A |
| Vomiting (reference: UK) | ||||
| 1 % increase in risk of vomiting | 0.97 (0.01) | 0.94, 0.99 | – | – |
| Netherlands × 1 % increase in risk | 0.95 (0.02) | 0.91, 1 | 0.96 (0.02) | 0.92, 0.99 |
| Germany × 1 % increase in risk | 0.92 (0.03) | 0.87, 0.98 | – | – |
| Sleep disturbance (reference: UK) | ||||
| 1 % increase in risk of sleep disturbance | 0.96 (0.01) | 0.95, 0.97 | – | – |
| Netherlands × 1 % increase in risk | 0.97 (0.01) | 0.95, 0.99 | – | – |
| France × 1 % increase in risk | 1.03 (0.01) | 1.01, 1.05 | 1.52 (0.20) | 1.17, 1.95 |
| Germany × 1 % increase in risk | – | – | 0.55 (0.17) | 0.31, 1.00 |
| Loss of appetite (reference: UK) | ||||
| 1 % increase in risk of loss of appetite | 0.96 (0.01) | 0.95, 0.97 | ||
| Netherlands × 1 % increase in risk | 0.93 (0.02) | 0.88, 0.97 | – | – |
| Germany × 1 % increase in risk | 0.91 (0.03) | 0.85, 0.97 | 0.97 (0.01) | 0.95, 0.99 |
| Frequency of medication (reference: UK) | ||||
| One additional administration in dosage per day | 0.79 (0.05) | 0.69, 0.9 | 0.95 (0.01) | 0.93, 0.98 |
| Germany × one additional administration in dosage | 0.60 (0.08) | 0.46, 0.79 | – | – |
| Spain × one additional administration in dosage | 1.37 (0.13) | 1.13, 1.66 | – | – |
| Italy × one additional administration in dosage | 1.39 (0.14) | 1.14, 1.69 | 1.06 (0.02) | 1.02, 1.10 |
| France × one additional administration in dosage | 1.25 (0.13) | 1.02, 1.53 | – | – |
| Netherlands × one additional administration in dosage | 0.95 (0.02) | 0.91, 0.99 | ||
CI confidence interval, OR odds ratio, SE standard error
This table shows the ORs of the significant attributes by country only in each group. In this table, the country is the dependent variable. Only countries that were significantly different from the UK (reference case) and the attributes that were most important to parents in each country are shown. For example, Spanish parents were more concerned than UK parents about the need to take medication more than once per day (OR = 1.37, 95 % CI = 1.13–1.66)
aCountries with a significant difference in overall patient preference compared with the UK, irrespective of attributes
bUK is base case profile